2023-11-13T18:47:44-05:00 2022-12-31 860839652 ECKELBERG & WIENSHIENK PC 5843 E ORANGE BLOSSOM LANE PHOENIX AZ 850186730 990 2022-01-01 860818253 INTERNATIONAL CANCER ADVOCACY NETWORK INTE 6026180183 27 WEST MORTEN AVENUE PHOENIX AZ 85021 MARCIA K HORN JD PRESIDENT AND CEO 6026180183 2023-11-13 true MARCIA HORN JD 999009999 false DUANE ECKELBERG P00106799 4804231888 2023-11-13 2022 2023-04-26 12:10:37Z ICAN MARCIA K HORN JD 27 WEST MORTEN AVENUE PHOENIX AZ 85021 1760767 false X WWW.ASKICAN.ORG X 1995 AZ ICAN ASSISTS STAGE IV CANCER PATIENTS WITH DIRECT PATIENT NAVIGATION AND CUSTOMIZED ADVOCACY SERVICES, INCLUDING PHYSICIAN REFERRALS, AS WELL AS ACCESS TO MOLECULAR PROFILING AND CLINICAL TRIALS. 5 4 1 172 0 971858 1378104 0 -1403 -1317 -21027 -18961 949428 1357826 145000 290100 0 209620 204274 0 10010 264648 421292 619268 915666 330160 442160 2896906 3351569 2875 7393 2894031 3344176 X ICAN'S MISSION IS TO ASSIST STAGE IV CANCER PATIENTS WITH DIRECT PATIENT NAVIGATION AND CUSTOMIZED ADVOCACY SERVICES, INCLUDING PHYSICIAN REFERRALS, AND ACCESS TO MOLECULAR PROFILING, CLINICAL TRIALS, AND COMPASSIONATE USE/EXPANDED ACCESS PROGRAMS. ICAN IS A PAN-HEME, PAN-TUMOR, AND PAN-RARE CANCER PATIENT ADVOCACY ORGANIZATION AND RESEARCH ADVOCACY ORGANIZATION. ICAN ALSO FOCUSES ON EXPANDING PATIENT ACCESS AND REDUCING HEALTH DISPARITIES. FROM TIME TO TIME, WE WILL AWARD GRANTS BASED ON SPECIAL EVENT REVENUES OR RESEARCH CAMPAIGNS TO SUPPORT OUR WORK TO DEFEAT RARE CANCERS, BUT ICAN'S PRIMARY MISSION IS OUR PATIENT PROGRAM SERVICES AND RESEARCH SERVICES ASSISTING CANCER PATIENTS AND THEIR CARE PARTNERS TO ENHANCE SURVIVAL AND ATTAIN THE HIGHEST POSSIBLE QUALITY OF LIFE. SEE ASKICAN.ORG AND EXON20GROUP.ORG false false 422719 290100 ICAN PATIENT SERVICES, INCLUDING RESEARCH ADVOCACY PROGRAMS OF WHICH 290,000 IN GRANTS WERE AWARDED TO THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, THE UNIVERSITY OF PENNSYLVANIA, JOHNS HOPKINS, AND THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO FOR PROJECTS RELATING TO MOLECULAR ALTERATIONS/RESISTANCE MECHANISMS, DRUG DEVELOPMENT W/ NEW MECHANISMS OF ACTION, EARLY DETECTION ASSAYS, & LEPTOMENINGEAL DISEASE. THESE PROJECTS COVER TWO MOLECULAR ALTERATIONS PRESENT IN MORE THAN TWENTY-FIVE SEPARATE TUMOR TYPES EACH (EGFR EXON 20 INSERTIONS AND HER2 EXON 20 INSERTIONS). OUR PATIENT SERVICES/ONCOLOGY NURSING SERVICES FOCUS ON HEMATOLOGICAL, SOLID TUMOR, SYNCHRONOUS/RARE CANCERS; PROTOCOL REVIEW, & SIDE EFFECTS MITIGATION. 193340 233779 PATIENT, CARE PARTNER, AND CLINICIAN EDUCATION/ U.S. AND GLOBAL PATIENT ACCESS PROGRAMS-FOCUSING ON PATIENT ACCESS TO MOLECULAR TESTING AND PRECISION MEDICINE; U.S. AND GLOBAL HEALTH EQUITY ISSUES; EARLY DETECTION (IMAGING AND MOLECULAR DIAGNOSTICS); ONGOING HEALTH INFORMATION PROJECTS; AND ACCESS ISSUES REGARDING EXPANDED ACCESS/PRE-APPROVAL ACCESS/COMPASSIONATE USE PROGRAMS IN THE U.S. AND COUNTRIES OUTSIDE THE U.S. 233779 MOLECULAR PROFILING CONNECTION SERVICES/CLINICAL TRIALS MATCHING SERVICES--ADVISING PATIENTS ON THE IMPORTANCE OF NEXT-GENERATION SEQUENCING AND MOLECULAR PROFILING (GENOMICS, PROTEOMICS, TRANSCRIPTOMICS, AND IMMUNE CELL STUDIES); REVIEWING MOLECULAR PROFILING REPORTS WITH PATIENTS AND THEIR CARE PARTNERS, CONVENING AD HOC MOLECULAR TUMOR BOARDS WHERE NEEDED; CONNECTING PATIENTS TO PRINCIPAL INVESTIGATORS AND STUDY TEAMS ON PAN- TUMOR/PAN-HEME/PAN-RARE CANCER BASIS. THE ORGANIZATION SPECIALIZES IN CLINICAL TRIAL ACCRUAL AND RETENTION ISSUES AS WELL AS CLINICAL TRIALS SITE SELECTION ISSUES. ONGOING WORK ON DECENTRALIZING TRIALS AND JUST-IN-TIME TRIAL CONCEPTS AS WELL AS TRANSFERRING PATIENTS FROM ONE CLINICAL TRIALS SITE TO ANOTHER MORE CONVENIENT SITE. 849838 true true false false false false false false false false true false false false false false false false false false false false false false true false false true false true false false false false false false true false true false false false false false false false false true 11 0 1 true false false false false false true true false false false false false false false false X 5 4 false false false false false false false true true false false true true true true true true true true false X X X CHAIR BOARD GOVERNANCE COMMITTEE 6026180183 27 WEST MORTEN AVENUE PHONEIX AZ 85021 SHERRY WEINSTEIN CHAIR-TTEES- 30.00 X X 0 0 0 ROBERT H TAMIS MD DECD NOV 22 VICE CHAIR S 20.00 X X 0 0 0 MARCIA K HORN JD PRESIDENT AN 90.00 X X 172000 0 20666 CATHY DALZELL CHAIR ADIVIS 5.00 X X 0 0 0 CHERYL J HINTZEN-GAINES CHAIR-HONORA 3.00 X X 0 0 0 SIDNEY M ROSEN ESQ FOUNDING CHA 10.00 X X 0 0 0 172000 20666 1 false true false J S HORN 27 W MORTEN AVE PHOENIX AZ 85021 GOVT AFFAIRS 149871 1 134168 1243936 356129 1378104 3327 3327 357356 362000 -4644 -4644 -4644 21980 134168 40941 -18961 -18961 1357826 -20278 X 290100 290100 172000 163400 3440 5160 20666 19633 413 620 11608 11028 232 348 516 516 8450 8450 278465 247465 31000 1163 1163 37472 32655 935 3882 3298 3298 33101 26189 6912 48617 48617 857 857 4502 1351 3151 DUES AND SEMINARS 2482 2217 265 BOOKS AND SUBSCRIPTIONS 2012 1683 329 BOARD/COMM DEVELOPMENT 172 172 BANK CHARGES 155 155 30 10 20 915666 849838 55818 10010 1143994 1229914 1086087 1446769 661505 7711 646665 653794 20160 14290 6802 2896906 3351569 2875 7393 2875 7393 X 2894031 3344176 2894031 3344176 2896906 3351569 X 442160 7985 X false false false X 1035777 1148479 987239 971858 1378104 5521457 1035777 1148479 987239 971858 1378104 5521457 5521457 234 698 521 912 3327 5692 23460 14560 10010 17160 65190 5592339 0.98730 0.98220 X PART II, LINE 10 GROSS GOLF EVENT PROCEEDS 65,190 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 7986 7711 275 653519 653519 653794 LIBERTY MUTUAL 82938 65258 17680 40941 FISTBUMP FUNDRA 68910 68910 151848 134168 17680 40941 40941 -23261 false HEYMACH LAB-MD ANDERSON CANCER CNTR 1515 HOLCOMBE BLVD HOUSTON TX 77030 746001118 150100 LUNG CANCER RESEARCH O'CONNOR LAB-CNTR CELLULAR IMMUNO 3400 CIVIC CENTER BLVD BLDG 421 PHILADELPHIA PA 19104 231352685 52500 IMMUNOTHERAPY RESRCH MD ANDERSON CANCER CENTER 1515 HOLCOMBE BLVD HOUSTON TX 77030 746001118 10000 SARCOMA RESEARCH BAYLIN LAB-JOHNS HOPKINS UNIVERSITY 3910 KESWICK RD N4327-B BALTIMORE MD 21211 520595110 20000 CANCER RESEARCH COV-IRT 57 SUMMER ST MEDFORD MA 02155 851947666 20000 EARLY DETECTION LUNG CANCER RESEARCH FOUNDATION 501 7TH AVE 401 NEW YORK NY 10018 141935776 37500 UCSF GRANT 6 SCHEDULE I, PAGE 1, PART I, LINE 2 ICAN HAS AWARDED RESEARCH GRANTS TO THE NAMED LABORATORIES AND INVESTIGATORS. REPRESENTATIVES OF ICAN AWARDEES PROVIDE PERIODIC UPDATES ON THEIR PROGRESS TO ICAN'S CEO AND TO MEMBERS OF THE GRANT COMMITTEE. GRANT MONIES ARE SOLELY SPENT WITHIN THE U.S. X X X false false false false false false false false false MARCIA K HORN JD PRESIDENT AND CEO 172000 20666 192666 J S HORN PHD FAMILY MEMBER 149871 INDEPENDNT CONTRACTR false SCHEDULE L, PART V SCH L, PART IV(1)-J.S. HORN, PHD, DIRECTOR, GOVERNMENTAL RELATIONS, FAMILY MEMBER OF BOARD MEMBER X 2 356129 DATE CONTRIBUTED FMV false true false FORM 990 - ORGANIZATION'S MISSION ICAN'S MISSION IS TO ASSIST STAGE IV CANCER PATIENTS WITH DIRECT PATIENT NAVIGATION AND CUSTOMIZED ADVOCACY SERVICES, INCLUDING PHYSICIAN REFERRALS, AND ACCESS TO MOLECULAR PROFILING, CLINICAL TRIALS, AND COMPASSIONATE USE/EXPANDED ACCESS PROGRAMS. ICAN IS A PAN-HEME, PAN-TUMOR, AND PAN-RARE CANCER PATIENT ADVOCACY ORGANIZATION AND RESEARCH ADVOCACY ORGANIZATION. ICAN ALSO FOCUSES ON EXPANDING PATIENT ACCESS AND REDUCING HEALTH DISPARITIES. FROM TIME TO TIME, WE WILL AWARD GRANTS BASED ON SPECIAL EVENT REVENUES OR RESEARCH CAMPAIGNS TO SUPPORT OUR WORK TO DEFEAT RARE CANCERS, BUT ICAN'S PRIMARY MISSION IS OUR PATIENT PROGRAM SERVICES AND RESEARCH SERVICES ASSISTING CANCER PATIENTS AND THEIR CARE PARTNERS TO ENHANCE SURVIVAL AND ATTAIN THE HIGHEST POSSIBLE QUALITY OF LIFE. SEE ASKICAN.ORG AND EXON20GROUP.ORG FORM 990, PAGE 6, PART VI, LINE 11B A COPY OF FORM 990 IS PROVIDED TO BOARD MEMBERS FOR THEIR REVIEW BEFORE THE FORM 990 IS FILED. THE CHAIRMAN OF BOARD OF TRUSTEES AND THE CHAIRS OF FINANCE/BOARD GOVERNANCE COMMITTEES REVIEW QUESTIONS AND COMMENTS, FORM 990, AND THE ORGANIZATION'S FINANCIAL STATMENTS WITH THE ORGANIZAZTION'S CEO. THE ORGANIZATION'S EXECUTIVE COMMITTEE THEN COMPLETES ITS REVIEW, AND FORM 990 IS FILED. FORM 990, PAGE 6, PART VI, LINE 12C BOARD MEMBERS ANNUALLY DISCLOSE IN WRITING ALL POTENTIAL OR ACTUAL CONFLICTS OF INTEREST TO THE BOARD GOVERNANCE COMMITTEE. FORM 990, PAGE 6, PART VI, LINE 15A SINCE 2003, THE ORGANIZATION HAS ANNUALLY REVIEWED THE CEO'S COMPENSATION, WITH AN ANALYSIS THAT INCLUDES COMPARISONS TO OTHER CANCER ORGANIZATION CHIEF EXECUTIVE OFFICERS' COMPENSATION AS WELL AS OTHER HEALTH CARE NONPROFIT ORGANIZATION CHIEF EXECUTIVE OFFICERS' SALARIES. SEVERAL YEARS AGO, THE ORGANIZATION BENEFITED FROM AN EXTERNAL ORGANIZATION'S ANALYSIS THAT IS DEVOTED ENTIRELY TO FOR-PROFIT AND NONPROFIT EXECUTIVES' COMPENSATION. THE PROCESS AT ICAN INVOLVES THE COMPENSATION COMMITTEE CHAIRMAN'S ANNUAL REVIEW OF THE CEO AND KEY STAFF'S COMPENSATION, ON BEHALF OF THE BOARD OF TRUSTEES, BASED ON INTERNAL AND EXTERNAL INPUTS AND REVIEWS AND THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF ANY SALARY INCREASE OR EMPLOYEE BENEFITS SUCH AS HEALTH INSURANCE AND OTHER INSURANCE. FORM 990, PAGE 6, PART VI, LINE 15B THE PROCESS AT ICAN INVOLVES THE COMPENSATION COMMITTEE CHAIRMAN'S ANNUAL REVIEW OF THE CEO AND KEY STAFF'S COMPENSATION, ON BEHALF OF THE BOARD OF TRUSTEES, BASED ON INTERNAL AND EXTERNAL INPUTS AND REVIEWS AND THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF ANY SALARY INCREASE OR EMPLOYEE BENEFITS SUCH AS HEALTH INSURANCE AND OTHER INSURANCE. FORM 990, PAGE 6, PART VI, LINE 19 THE ORGANIZATION'S WEBSITE HAS AN EXTENSIVE BOARD GOVERNANCE SECTION. THE ORGANIZATION'S FORM 990 AS WELL AS ALL BOARD GOVERNANCE DOCUMENTS, INCLUDING CONFLICT OF INTEREST POLICY, WHISTLEBLOWER POLICY, AND DOCUMENTS RETENTION POLICY, ARE AVAILABLE ON ICAN'S WEBSITE (COMPENDIUM OF BOARD POLICIES) AND AT AVAILABLE AT GUIDESTAR/CANDID. FORM 990, PART IX, LINE 11G PATIENT SERVICES 92,900 20,000 0 PATIENT ACCESS/HEALTH EQUITY 153,621 6,000 0 OUTSIDE SERVICES 944 5,000 0 TOTAL 247,465 31,000 0 FORM 990, PART XI, LINE 9 PRIOR PERIOD ADJUSTMENT 7,985